drug
as of 2026-07-01Lu AF35700
MeSH C000726227
at a glance
small molecule
Pre-approval / investigational in the US
Developed by H. Lundbeck A/S
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
5
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
NCT02892422Phase 3Completed
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
NCT03230864Phase 3Terminated
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
NCT02717195Phase 3Completed
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
NCT02333487Phase 1Completed
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
NCT02202226Phase 1Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication